A first HRT consultation is most useful when it connects your symptoms with a clear set of treatment choices. You do not need to arrive knowing which hormone or dose to request. Bring the history that affects the decision, identify what you want to improve, and leave understanding the next step. This guide helps organize a menopause hormone therapy appointment, including questions about contraception, uterine protection, product instructions, testing, risks, and follow-up.
Write down the problem you most want solved
Start with two or three concerns rather than a long list ranked equally. Describe their frequency and effect: night sweats that wake you several nights a week, hot flashes during work, or discomfort that makes intimacy painful. Note when they began and whether they vary with your cycle, sleep, or other changes.
A specific description helps the clinician decide whether systemic HRT, local treatment, a nonhormonal option, or further evaluation fits the problem. It also creates a baseline for judging response. ACOG’s hormone therapy overview explains the main treatment categories. Our complete HRT guide provides background if you want to understand those categories before the visit.
Prepare a menstrual and surgical timeline
Record the last natural period if known, recent cycle changes, and any bleeding between periods or after sex. If periods are absent because of contraception or surgery, say so. Mention heavy bleeding, pelvic pain, prior polyps or fibroids, and any earlier evaluation of the uterine lining.
List hysterectomy and ovarian surgery separately. Removing the uterus does not necessarily remove the ovaries, and the distinction affects both treatment and interpretation of menopause timing. If the surgery details are uncertain, bring available records or ask how to obtain them. This information often contributes more to a useful assessment than an isolated hormone test taken without considering medicines, age, or menstrual history.
Bring the medical history that changes the options
Include personal and family cancer history, blood clots, stroke, heart attack, liver disease, migraines, and blood pressure concerns. For a family history, note the relative and age at diagnosis when possible. Also mention smoking, planned surgery, recent major illness, and any specialist advice about hormone use.
Some histories make systemic HRT unsuitable or call for additional review. Low-dose vaginal treatment can involve a different assessment, particularly when local symptoms persist. The risks and benefits article explains why the details matter. The purpose is to identify an appropriate option, not to make you determine eligibility yourself. Bring questions about any diagnosis whose relevance you do not understand.
Include every medicine and hormone product
Bring names, strengths, and instructions for prescription medicines, contraception, nonprescription products, supplements, and creams. Include items obtained from another practice or online source. A product marketed as natural can still contain an active hormone and affect interpretation of symptoms or treatment exposure.
If you already use a patch, gel, vaginal product, or progesterone, show the exact label. Similar product names can conceal different strengths or purposes. Do not stop medicines independently before the appointment to obtain a cleaner hormone test. Ask whether any changes are necessary and who should coordinate them. A complete list helps prevent accidental duplication and makes it easier to give product-specific instructions later.
Clarify contraception and pregnancy potential
Perimenopause can include irregular ovulation, so unpredictable periods do not establish that pregnancy is impossible. Menopause HRT does not provide contraception. If pregnancy is possible, discuss whether it is desired and how contraception fits with symptom treatment. NICE’s menopause guidance includes the need for contraceptive advice during the transition.
Bring the type and date of any intrauterine device or implant and the name of any hormonal contraceptive. Its role in pregnancy prevention may differ from its suitability within a menopause HRT regimen. Do not combine treatments or infer that a device provides endometrial protection without specific confirmation. Our perimenopause guide explains why these decisions often need to be considered together.
Ask whether the proposed treatment is systemic or local
The distinction determines what symptoms the medicine is intended to treat. Systemic estrogen can relieve hot flashes and night sweats; low-dose vaginal estrogen primarily treats local vaginal and related symptoms. Some vaginal rings are systemic, so the route alone is not enough to identify the treatment category.
Ask the clinician to name the main expected benefit and explain why the proposed formulation fits your history. If vaginal symptoms remain despite systemic HRT, ask whether a local treatment or examination is appropriate rather than assuming the systemic dose must rise. The local versus systemic comparison provides examples of how the same word, estrogen, can describe treatments with different purposes.
Understand how the uterine lining will be protected
If you have a uterus and are prescribed systemic estrogen, ask which part of the plan provides adequate endometrial protection. Usually this is a progestogen, although specific approved alternatives exist. Clarify whether the regimen is cyclic or continuous and what bleeding pattern is expected. The Menopause Society’s position statement explains why protection is necessary.
Do not assume an over-the-counter progesterone cream can replace the prescribed component. If a medicine causes side effects, ask about alternatives rather than stopping that component while continuing estrogen. The estrogen and progesterone article explains the terminology and common exceptions, including low-dose vaginal estrogen. You should leave knowing the purpose of each prescription, not simply the order in which to take it.
Ask what testing would change
In otherwise healthy people 45 and older with typical symptoms, menopause is usually identified clinically. FSH testing is used more selectively in younger or uncertain cases, and other tests may investigate separate problems such as anemia or thyroid disease. A large panel is not automatically a more complete assessment. NICE’s recommendations describe this approach.
For each proposed test, ask what question it answers and how the result could change treatment. Be cautious about routine saliva or urine testing marketed to create an exact personalized hormone balance. ACOG does not recommend adjunct hormone testing to prescribe or dose compounded menopause therapy. Our testing and follow-up guide explains the difference between useful targeted testing and repeated numbers without a clear clinical purpose.
Discuss approved and compounded products clearly
Some FDA-approved estradiol and progesterone products are bioidentical, meaning their molecules match hormones made by the body. Bioidentical does not mean a product must be compounded, and it does not prove superior safety. ACOG recommends approved products over routine compounded menopause therapy when approved options are available. Its clinical consensus addresses the evidence and quality considerations.
If compounding is proposed, ask what specific need cannot be met by an approved option and what uncertainties that introduces. Also ask how a long-acting product would be managed if side effects occur. The answer should relate to your clinical situation rather than a general claim that customization is always better or that natural ingredients eliminate risk.
Get practical instructions before the prescription starts
Ask how and when to use the exact medicine, what to do after a missed dose, and how to store it. For patches, clarify application and replacement instructions; for gels or sprays, ask about drying and contact precautions; for vaginal products, ask about applicator use and maintenance directions. Products within a category can differ.
Also discuss access, cost, and what to do if the pharmacy cannot supply the exact formulation. A substitute may need new instructions or prescribing review. Confirm whether any previous hormone product should stop when the new one starts. Written directions reduce the chance of unintentionally combining regimens or using a new product according to an old label.
Agree on follow-up and a bleeding plan
NICE recommends an initial review at about three months and annual review thereafter, with earlier assessment for concerns. Ask which symptoms to track and how to contact the practice between visits. Side effects, persistent symptoms, and changes in medical history can all justify earlier review.
Discuss expected bleeding and what should prompt contact. Postmenopausal bleeding requires evaluation, and ACOG updated its initial assessment guidance in April 2026. The ACOG update reinforces why new bleeding should not be cleared by an old online rule or assumed to be a harmless medication effect. Severe bleeding with weakness or faintness needs urgent care. The plan should make the response understandable before a problem occurs.
Leave with a decision and a next step
The outcome may be a prescription, further evaluation, a nonhormonal treatment, or time to consider your preferences. Each can be a useful result if the reasoning and next step are clear. Ask the clinician to summarize the intended benefit, the main risks relevant to you, and what would lead to a change in the plan.
If treatment starts, save the instructions and baseline symptom summary for follow-up. If it does not, clarify how the symptoms will be addressed and whether specialist input is needed. Recent FDA warning changes can inform the conversation, but the current label and your history still matter. A good consultation leaves you able to explain the plan in your own words and know when it will be revisited.
Related reading
- Menopause Hormone Therapy: Benefits, Options, and Questions to Ask
- Estrogen Patch vs. Pill: Comparing Menopause HRT Routes
- HRT Risks and Benefits: Age, Timing, and Personal Medical History
- HRT Testing and Follow-Up: Symptoms, Bleeding, and Laboratory Questions
- Menopausal skin care and changing skin needs
- Estriol face cream versus menopause hormone therapy
Educational information. Individual treatment selection, prescription directions, and follow-up belong with the treating clinician. Linked guidance and source versions checked September 15, 2026. Medication instructions and evidence can differ by formulation and clinical use. Photographs are illustrative and do not show treatment outcomes.
